Product Information
DEXTROAMPH-AMPHET ER 37.5 MG CP is a generic product labeled by SpecGx LLC, priced at $8.6544 per EA under NDC 00406080701. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Aug 31, 2023. Its Orange Book therapeutic-equivalence code is AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
DEXTROAMPH-AMPHET ER 37.5 MG CP
DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATEStrength
9.375; 9.375; 9.375; 9.375 mg/1; mg/1; mg/1; mg/1
Manufacturer
SpecGx LLCNDC
00406080701
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AMPHETAMINE ASPARTATE MONOHYDRATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATEApproval Type
Generic (ANDA)
FDA Application
ANDA211546FDA Approved
8/31/2023
TE Code
AB2
On Market Since
11/1/2023
Pharmacological Classes
Price Statistics
The NADAC for DEXTROAMPH-AMPHET ER 37.5 MG CP has been published 129 times since Apr 17, 2024, and over the history we have for it it has risen 9.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.6544 per EA |
|---|---|
| All-time high | $8.8791 (Jul 16, 2025) |
| All-time low | $7.7685 (May 22, 2024) |
| 52-week high | $8.8545 |
| 52-week low | $8.1472 |
| Median price | $8.4643 |
| Average price | $8.4462 |
| Largest weekly change | +10.9% (Jun 19, 2024) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
SpecGx LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DEXTROAMPH-AMPHET ER 37.5 MG CP?
The current National Average Drug Acquisition Cost (NADAC) for DEXTROAMPH-AMPHET ER 37.5 MG CP, manufactured by SpecGx LLC, is $8.6544 per EA (NDC 00406080701), effective Sep 30, 2026.
How has the price of DEXTROAMPH-AMPHET ER 37.5 MG CP changed over time?
Over the history we have for it, the NADAC for DEXTROAMPH-AMPHET ER 37.5 MG CP has risen 9.7%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for DEXTROAMPH-AMPHET ER 37.5 MG CP?
Since Apr 17, 2024, the NADAC for DEXTROAMPH-AMPHET ER 37.5 MG CP has ranged from a low of $7.7685 (May 22, 2024) to a high of $8.8791 (Jul 16, 2025), with a median of $8.4643 per EA.
Are there cheaper alternatives to DEXTROAMPH-AMPHET ER 37.5 MG CP?
No other NADAC-published product currently shares the active ingredient and strength of DEXTROAMPH-AMPHET ER 37.5 MG CP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DEXTROAMPH-AMPHET ER 37.5 MG CP?
DEXTROAMPH-AMPHET ER 37.5 MG CP (NDC 00406080701) is labeled by SpecGx LLC, and CMS classifies it as a generic product.